Diabetes & Metabolism Journal

Tae Seo Sohn (Sohn TS)

9 Articles

Cardiovascular Risk/Epidemiology
Real-World Treatment Patterns according to Clinical Practice Guidelines in Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Korea: Multicenter, Retrospective, Observational Study: Ye Seul Yang, Nam Hoon Kim, Jong Ha Baek, Seung-Hyun Ko, Jang Won Son, Seung-Hwan Lee, Sang Youl Rhee, Soo-Kyung Kim, Tae Seo Sohn, Ji Eun Jun, In-Kyung Jeong, Chong Hwa Kim, Keeho Song, Eun-Jung Rhee, Junghyun Noh, Kyu Yeon Hur, Committee of Clinical Practice Guidelines, Korean Diabetes Association; Diabetes Metab J. 2024;48(2):279-289. Published online January 26, 2024; DOI: https://doi.org/10.4093/dmj.2023.0225

3,005 View
339 Download
3 Web of Science
3 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Recent diabetes management guidelines recommend that sodium-glucose cotransporter 2 inhibitors (SGLT2is) or glucagon-like peptide 1 receptor agonists (GLP-1RAs) with proven cardiovascular benefits should be prioritized for combination therapy in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease (CVD). This study was aimed at evaluating SGLT2i or GLP-1RA usage rates and various related factors in patients with T2DM and established CVD.
Methods
We enrolled adults with T2DM aged ≥30 years who were hospitalized due to established CVD from January 2019 to May 2020 at 13 secondary and tertiary hospitals in Korea in this retrospective observational study.
Results
Overall, 2,050 patients were eligible for analysis among 2,107 enrolled patients. The mean patient age, diabetes duration, and glycosylated hemoglobin level were 70.0 years, 12.0 years, and 7.5%, respectively. During the mean follow-up duration of 9.7 months, 25.7% of the patients were prescribed SGLT2is after CVD events. However, only 1.8% were prescribed GLP-1RAs. Compared with SGLT2i non-users, SGLT2i users were more frequently male and obese. Furthermore, they had a shorter diabetes duration but showed worse glycemic control and better renal function at the time of the event. GLP-1RA users had a longer duration of diabetes and worse glycemic control at the time of the event than GLP-1RA non-users.
Conclusion
The SGLT2i or GLP-1RA prescription rates were suboptimal in patients with T2DM and established CVD. Sex, body mass index, diabetes duration, glycemic control, and renal function were associated with the use of these agents.

Citations

Citations to this article as recorded by

Enhancing Patient Outcomes: Prioritizing SGLT2is and GLP-1RAs in Diabetes with CVD
Gwanpyo Koh
Diabetes & Metabolism Journal.2024; 48(2): 208. CrossRef
Cardiovascular Disease & Diabetes Statistics in Korea: Nationwide Data 2010 to 2019
Jin Hwa Kim, Junyeop Lee, Kyungdo Han, Jae-Taek Kim, Hyuk-Sang Kwon
Diabetes & Metabolism Journal.2024; 48(6): 1084. CrossRef
Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
Kyoung Hwa Ha, Soyoung Shin, EunJi Na, Dae Jung Kim
Journal of Diabetes Investigation.2024;[Epub] CrossRef

Drug Regimen
Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial: Kyung Ah Han, Yong Hyun Kim, Doo Man Kim, Byung Wan Lee, Suk Chon, Tae Seo Sohn, In Kyung Jeong, Eun-Gyoung Hong, Jang Won Son, Jae Jin Nah, Hwa Rang Song, Seong In Cho, Seung-Ah Cho, Kun Ho Yoon; Diabetes Metab J. 2023;47(6):796-807. Published online February 9, 2023; DOI: https://doi.org/10.4093/dmj.2022.0315

43,074 View
708 Download
7 Web of Science
8 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development. This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with type 2 diabetes mellitus (T2DM) against dapagliflozin.
Methods
In this multicenter, double-blind, randomized, phase 3 study, 200 patients were randomized to receive enavogliflozin 0.3 mg/day (n=101) or dapagliflozin 10 mg/day (n=99) in addition to ongoing metformin therapy for 24 weeks. The primary objective of the study was to prove the non-inferiority of enavogliflozin to dapagliflozin in glycosylated hemoglobin (HbA1c) change at week 24 (non-inferiority margin of 0.35%) (Clinical trial registration number: NCT04634500).
Results
Adjusted mean change of HbA1c at week 24 was –0.80% with enavogliflozin and –0.75% with dapagliflozin (difference, –0.04%; 95% confidence interval, –0.21% to 0.12%). Percentages of patients achieving HbA1c <7.0% were 61% and 62%, respectively. Adjusted mean change of fasting plasma glucose at week 24 was –32.53 and –29.14 mg/dL. An increase in urine glucose-creatinine ratio (60.48 vs. 44.94, P<0.0001) and decrease in homeostasis model assessment of insulin resistance (–1.85 vs. –1.31, P=0.0041) were significantly greater with enavogliflozin than dapagliflozin at week 24. Beneficial effects of enavogliflozin on body weight (–3.77 kg vs. –3.58 kg) and blood pressure (systolic/diastolic, –5.93/–5.41 mm Hg vs. –6.57/–4.26 mm Hg) were comparable with those of dapagliflozin, and both drugs were safe and well-tolerated.
Conclusion
Enavogliflozin added to metformin significantly improved glycemic control in patients with T2DM and was non-inferior to dapagliflozin 10 mg, suggesting enavogliflozin as a viable treatment option for patients with inadequate glycemic control on metformin alone.

Citations

Citations to this article as recorded by

Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials
Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park
Cardiovascular Diabetology.2024;[Epub] CrossRef
A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
Tae Seo Sohn, Kyung‐Ah Han, Yonghyun Kim, Byung‐Wan Lee, Suk Chon, In‐Kyung Jeong, Eun‐Gyoung Hong, Jang Won Son, JaeJin Na, Jae Min Cho, Seong In Cho, Wan Huh, Kun‐Ho Yoon
Diabetes, Obesity and Metabolism.2024; 26(6): 2248. CrossRef
The effect of renal function on the pharmacokinetics and pharmacodynamics of enavogliflozin, a potent and selective sodium‐glucose cotransporter‐2 inhibitor, in type 2 diabetes
Sae Im Jeong, Mu Seong Ban, Jun‐Gi Hwang, Min‐Kyu Park, Soo Lim, Sejoong Kim, Soon Kil Kwon, Yoonjin Kim, Jae Min Cho, Jae Jin Na, Wan Huh, Jae‐Yong Chung
Diabetes, Obesity and Metabolism.2024; 26(7): 2588. CrossRef
Long‐term efficacy and safety of enavogliflozin in Korean people with type 2 diabetes: A 52‐week extension of a Phase 3 randomized controlled trial
Soo Heon Kwak, Kyung Ah Han, Eun Sook Kim, Sung Hee Choi, Jong Chul Won, Jae Myung Yu, Seungjoon Oh, Hye Jin Yoo, Chong Hwa Kim, Kyung‐Soo Kim, SungWan Chun, Yong Hyun Kim, Seung Ah Cho, Da Hye Kim, Kyong Soo Park
Diabetes, Obesity and Metabolism.2024; 26(10): 4203. CrossRef
Role of novel sodium glucose co-transporter-2 inhibitor enavogliflozin in type-2 diabetes: A systematic review and meta-analysis
Deep Dutta, B.G. Harish, Beatrice Anne, Lakshmi Nagendra
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(8): 102816. CrossRef
Characteristics of the Latest Therapeutic Agent for Diabetes
Nuri Yun
The Journal of Korean Diabetes.2023; 24(3): 148. CrossRef
Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD)
Iryna Kostitska, Nadia Protas, Liliia Petrovska
Diabetes Obesity Metabolic Syndrome.2023; (5): 8. CrossRef
Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin
Sang Youl Rhee
Diabetes & Metabolism Journal.2023; 47(6): 769. CrossRef

Drug/Regimen
Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus: Soon-Jib Yoo, Sang-Ah Chang, Tae Seo Sohn, Hyuk-Sang Kwon, Jong Min Lee, Sungdae Moon, Pieter Proot, Päivi M Paldánius, Kun Ho Yoon; Diabetes Metab J. 2021;45(6):954-959. Published online November 12, 2020; DOI: https://doi.org/10.4093/dmj.2020.0173

56,575 View
405 Download
4 Web of Science
3 Crossref

Graphical Abstract Abstract PDF Supplementary Material PubReader ePub

We assessed the glycaemic durability with early combination (EC; vildagliptin+metformin [MET], n=22) versus MET monotherapy (n=17), among newly-diagnosed type 2 diabetes mellitus (T2DM) enrolled (between 2012 and 2014) in the VERIFY study from Korea (n=39). Primary endpoint was time to initial treatment failure (TF) (glycosylated hemoglobin [HbA1c] ≥7.0% at two consecutive scheduled visits after randomization [end of period 1]). Time to second TF was assessed when both groups were receiving and failing on the combination (end of period 2). With EC the risk of initial TF significantly reduced by 78% compared to MET (n=3 [15%] vs. n=10 [58.7%], P=0.0228). No secondary TF occurred in EC group versus five patients (29.4%) in MET. Patients receiving EC treatment achieved consistently lower HbA1c levels. Both treatment approaches were well tolerated with no hypoglycaemic events. In Korean patients with newly diagnosed T2DM, EC treatment significantly and consistently improved the long-term glycaemic durability as compared with MET.

Citations

Citations to this article as recorded by

Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
Ji-Yeon Park, Joonyub Lee, Yoon-Hee Choi, Kyung Wan Min, Kyung Ah Han, Kyu Jeung Ahn, Soo Lim, Young-Hyun Kim, Chul Woo Ahn, Kyung Mook Choi, Kun-Ho Yoon
Diabetes & Metabolism Journal.2024; 48(5): 915. CrossRef
2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
Diabetes & Metabolism Journal.2023; 47(5): 575. CrossRef
2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
Kyu Yeon Hur, Min Kyong Moon, Jong Suk Park, Soo-Kyung Kim, Seung-Hwan Lee, Jae-Seung Yun, Jong Ha Baek, Junghyun Noh, Byung-Wan Lee, Tae Jung Oh, Suk Chon, Ye Seul Yang, Jang Won Son, Jong Han Choi, Kee Ho Song, Nam Hoon Kim, Sang Yong Kim, Jin Wha Kim,
Diabetes & Metabolism Journal.2021; 45(4): 461. CrossRef

Age at Diagnosis and the Risk of Diabetic Nephropathy in Young Patients with Type 1 Diabetes Mellitus (Diabetes Metab J 2021;45:46-54): Ye Seul Yang, Tae Seo Sohn; Diabetes Metab J. 2021;45(2):277-278. Published online March 25, 2021; DOI: https://doi.org/10.4093/dmj.2021.0028

4,177 View
83 Download

PDF PubReader ePub

Smoking as a Target for Prevention of Diabetes: Ye Seul Yang, Tae Seo Sohn; Diabetes Metab J. 2020;44(3):402-404. Published online June 29, 2020; DOI: https://doi.org/10.4093/dmj.2020.0126

5,483 View
77 Download
2 Web of Science
2 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

Association between Smoking Status and the Risk of Hip Fracture in Patients with Type 2 Diabetes: A Nationwide Population-Based Study
Se-Won Lee, Jun-Young Heu, Ju-Yeong Kim, Jinyoung Kim, Kyungdo Han, Hyuk-Sang Kwon
Endocrinology and Metabolism.2023; 38(6): 679. CrossRef
The Global Burden of Type 2 Diabetes Attributable to Tobacco: A Secondary Analysis From the Global Burden of Disease Study 2019
Jianjun Bai, Fang Shi, Yudiyang Ma, Donghui Yang, Chuanhua Yu, Jinhong Cao
Frontiers in Endocrinology.2022;[Epub] CrossRef

Lifestyle
Body Fat Is Related to Sedentary Behavior and Light Physical Activity but Not to Moderate-Vigorous Physical Activity in Type 2 Diabetes Mellitus: Keun Hee An, Kyung Ah Han, Tae Seo Sohn, Ie Byung Park, Hae Jin Kim, Sung Dae Moon, Kyung Wan Min; Diabetes Metab J. 2020;44(2):316-325. Published online November 12, 2019; DOI: https://doi.org/10.4093/dmj.2019.0029

6,734 View
149 Download
11 Web of Science
12 Crossref

Abstract PDF PubReader

Background

Sedentary behavior (SB) has emerged as a new risk factor for cardiovascular accidents. We investigated whether physical activity levels or SB were related to percent body fat (%BF) in type 2 diabetes mellitus (T2DM).

Methods

In this cross sectional study, we measured the duration of SB, light physical activity (LPA), moderate to vigorous physical activity (MVPA), total energy expenditure, and step counts using a wireless activity tracker (Fitbit HR; FB) for 7 days in free-living conditions, along with %BF using a bio impedance analyzer (Inbody; Biospace) in 120 smartphone users with T2DM. Subjects were divided into exercise (Exe, n=68) and non-exercise (nonExe, n=52) groups based on self-reports of whether the recommended exercises (30 min/day, 3 days/week for 3 months) were performed. SBt, LPAt, MVPAt were transformed from SB, LPA, MVPA for normally distributed variables.

Results

Participants were: female, 59.2%; age, 59.3±8.4 years; body mass index, 25.5±3.4 kg/m²; glycosylated hemoglobin (HbA1c), 7.6%±1.2%; %BF, 30.4%±7.1%. They performed SB for 15.7±3.7 hr/day, LPA for 4.4±1.7 hr/day, and MVPA for 0.9±0.8 hr/day. The %BF was related to SBt and LPAt, but not to MVPA after adjustments for age, gender, and HbA1c. VPA was significantly higher in the Exe group than in the nonExe group, but SB, LPA, and moderate physical activity were not different. Predicted %BF was 89.494 to 0.105 (age), −13.047 (gender), −0.507 (HbA1c), −7.655 (LPAt) (F[4, 64]=62.929, P<0.001), with an R² of 0.785 in multiple linear regression analysis.

Conclusion

Reduced body fat in elderly diabetic patients might be associated with reduced inactivity and increased LPA.

Citations

Citations to this article as recorded by

The Power of Movement: Linking Physical Activity with Nutritional Health and Blood Sugar Balance in a Dalmatian Type 2 Diabetic Population
Josipa Radić, Andrej Belančić, Hana Đogaš, Marijana Vučković, Tina Đogaš, Leida Tandara, Marina Grubić, Lucija Šolić Šegvić, Ivana Novak, Mislav Radić
Nutrients.2025; 17(1): 187. CrossRef
Explanatory variables of objectively measured 24-h movement behaviors in people with prediabetes and type 2 diabetes: A systematic review
Lotte Bogaert, Iris Willems, Patrick Calders, Eveline Dirinck, Manon Kinaupenne, Marga Decraene, Bruno Lapauw, Boyd Strumane, Margot Van Daele, Vera Verbestel, Marieke De Craemer
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(4): 102995. CrossRef
Associations of nonoccupational sedentary behaviors with cardiometabolic outcomes: coronary artery risk development in young adults (CARDIA)
Gabriel Zieff, Michael P Bancks, Kelley Pettee Gabriel, Bethany Barone Gibbs, Justin B Moore, Jared P Reis, Keeron Stone, Lee Stoner
Annals of Behavioral Medicine.2024;[Epub] CrossRef
Association between depression, anemia and physical activity using isotemporal substitution analysis
Hee-kyoung Nam, Jungmi Park, Sung-il Cho
BMC Public Health.2023;[Epub] CrossRef
The Impact of Wearable Technologies in Health Research: Scoping Review
Sophie Huhn, Miriam Axt, Hanns-Christian Gunga, Martina Anna Maggioni, Stephen Munga, David Obor, Ali Sié, Valentin Boudo, Aditi Bunker, Rainer Sauerborn, Till Bärnighausen, Sandra Barteit
JMIR mHealth and uHealth.2022; 10(1): e34384. CrossRef
The Correlation of Prediabetes and Type 2 Diabetes With Adiposity in Adults
Juan Sun, Zhen Liu, Zimu Zhang, Ziyang Zeng, Weiming Kang
Frontiers in Nutrition.2022;[Epub] CrossRef
The Physical Activity Assessment of Adults With Type 2 Diabetes Using Accelerometer-Based Cut Points: Scoping Review
Ioana A Moldovan, Alexa Bragg, Anna S Nidhiry, Barbara A De La Cruz, Suzanne E Mitchell
Interactive Journal of Medical Research.2022; 11(2): e34433. CrossRef
Effects of 4 Weeks of a Technique-Specific Protocol with High-Intensity Intervals on General and Specific Physical Fitness in Taekwondo Athletes: An Inter-Individual Analysis
Alex Ojeda-Aravena, Tomás Herrera-Valenzuela, Pablo Valdés-Badilla, Jorge Cancino-López, José Zapata-Bastias, José Manuel García-García
International Journal of Environmental Research and Public Health.2021; 18(7): 3643. CrossRef
Inter-Individual Variability of a High-Intensity Interval Training With Specific Techniques vs. Repeated Sprints Program in Sport-Related Fitness of Taekwondo Athletes
Alex Ojeda-Aravena, Tomás Herrera-Valenzuela, Pablo Valdés-Badilla, Jorge Cancino-López, José Zapata-Bastias, José Manuel García-García
Frontiers in Physiology.2021;[Epub] CrossRef
EFFECT OF SPORTS MEDICINE ON REDUCING BODY FAT PERCENTAGE AND LEAN BODY MASS
Chunyan Fan
Revista Brasileira de Medicina do Esporte.2021; 27(7): 714. CrossRef
Validation of the effectiveness of a digital integrated healthcare platform utilizing an AI-based dietary management solution and a real-time continuous glucose monitoring system for diabetes management: a randomized controlled trial
Sung Woon Park, Gyuri Kim, You-Cheol Hwang, Woo Je Lee, Hyunjin Park, Jae Hyeon Kim
BMC Medical Informatics and Decision Making.2020;[Epub] CrossRef
Brain activity during a working memory task in different postures: an EEG study
Ju-Yeon Jung, Hwi-Young Cho, Chang-Ki Kang
Ergonomics.2020; 63(11): 1359. CrossRef

Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019;43:582–9): Tae Seo Sohn; Diabetes Metab J. 2019;43(6):909-910. Published online December 26, 2019; DOI: https://doi.org/10.4093/dmj.2019.0205

3,588 View
53 Download

PDF PubReader

Letter: Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2019;43;276-86): Hannah Seok, Tae Seo Sohn; Diabetes Metab J. 2019;43(4):545-546. Published online August 20, 2019; DOI: https://doi.org/10.4093/dmj.2019.0130

3,427 View
40 Download
1 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

Deciphering the binding behavior and interaction mechanism of apigenin and α-glucosidase based on multi-spectroscopic and molecular simulation studies
Fuqiang Liang, Keyu Meng, Xinran Pu, Yubo Cao, Yumeng Shi, Jiayi Shi
International Journal of Biological Macromolecules.2024; 264: 130535. CrossRef

Severe Hypoglycemia Is a Serious Complication and Becoming an Economic Burden in Diabetes: Won Chul Ha, Su Jin Oh, Ji Hyun Kim, Jung Min Lee, Sang Ah Chang, Tae Seo Sohn, Hyun Shik Son; Diabetes Metab J. 2012;36(4):280-284. Published online August 20, 2012; DOI: https://doi.org/10.4093/dmj.2012.36.4.280

5,347 View
38 Download
38 Crossref

Abstract PDF PubReader

Background

The prevalence of hypoglycemia is increasing due to the growing incidence of diabetes and the latest strict guidelines for glycated hemoglobin (HbA1c) levels under 7%. This study examined the clinical characteristics, causal factors, and medical costs of severely hypoglycemic patients in an emergency room (ER) of Uijeongbu St. Mary's Hospital.

Methods

The study consisted of a retrospective analysis of the characteristics, risk factors, and medical costs of 320 severely hypoglycemic patients with diabetes who presented to an ER of Uijeongbu St. Mary's Hospital from January 1, 2006 to December 31, 2009.

Results

Most hypoglycemic patients (87.5%, 280/320) were over 60 years old with a mean age of 69.5±10.9 years and a mean HbA1c level of 6.95±1.46%. Mean serum glucose as noted in the ER was 37.9±34.5 mg/dL. Renal function was decreased, serum creatinine was 2.0±2.1 mg/dL and estimated glomerular filtration rate (eGFR) was 48.0±33.6 mL/min/1.73 m². In addition, hypoglycemic patients typically were taking sulfonylureas or insulin and a variety of other medications, and had a long history of diabetes.

Conclusion

Severe hypoglycemia is frequent in older diabetic patients, subjects with low HbA1c levels, and nephropathic patients. Therefore, personalized attention is warranted, especially in long-term diabetics with multiple comorbidities who may not have been properly educated or may need re-education for hypoglycemia.

Citations

Citations to this article as recorded by

Incidence and influencing factors for hypoglycemia in maintenance hemodialysis patients with diabetic kidney disease: a meta-analysis
Feifei Jiang
American Journal of Translational Research.2024; 16(10): 5216. CrossRef
Direct costs of severe hypoglycemia events in individuals with diabetes mellitus: a perspective from the Colombian health system - a single-center study
Natalia A. Rojas-Henao, Michael Garcia-Rivera, Ana C. Hernandez-Herrera, Juliana Díaz-Giraldo, Carlos E. Builes-Montaño
Hospital Practice.2024; : 1. CrossRef
The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review
Samuel J Westall, Ram Prakash Narayanan, Simon Watmough, Greg Irving, Niall Furlong, Sid McNulty, Sumudu Bujawansa, Kevin Hardy
Clinical Medicine.2022; 22(3): 257. CrossRef
Analysis of recurrent hypoglycemic events
Chenchen Ma, Yongming Qu, Haoda Fu
Journal of Biopharmaceutical Statistics.2021; 31(1): 5. CrossRef
ROLE OF OCTREOTIDE IN MANAGEMENT OF SULPHONYLUREA - INDUCED REFRACTORY HYPOGLYCEMIA : A CASE REPORT
Akshay Kothari, Kiran Shah
INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 3. CrossRef
Hospitalization Costs Due to Hypoglycemia in Patients with Diabetes: A Microcosting Approach
João P. Ferreira, Francisco Araújo, Jorge Dores, Lèlita Santos, Estevão Pape, Mónica Reis, Árcia Chipepo, Edite Nascimento, Ana Baptista, Vanessa Pires, Carlos Marques, Adriana S. Lages, João Conceição, Pedro A. Laires, João Pelicano-Romano, Sílvia Alão
Diabetes Therapy.2020; 11(10): 2237. CrossRef
The Burden of Hypoglycemia in Patients With Insulin-Treated Diabetes Mellitus in China: Analysis of Electronic Medical Records From 4 Tertiary Hospitals
Xiaomeng Yue, Jiuhong Wu, Zhen Ruan, Michael L. Wolden, Lanting Li, Yong Lin
Value in Health Regional Issues.2020; 21: 17. CrossRef
A closer look at the 2019 Beers criteria
Rishabh Sharma, Malika Arora, Ravinder Garg, Parveen Bansal
Drugs & Therapy Perspectives.2020; 36(3): 116. CrossRef
Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control
Jee Hee Yoo, Jae Hyeon Kim
Diabetes & Metabolism Journal.2020; 44(6): 828. CrossRef
Comparison of clinical pharmacy specialists and usual care in outpatient management of hyperglycemia in Veterans Affairs medical centers
Heather L Ourth, Kwan Hur, Anthony P Morreale, Francesca Cunningham, Bharat Thakkar, Sherrie Aspinall
American Journal of Health-System Pharmacy.2019; 76(1): 26. CrossRef
Cost‐effectiveness of the psycho‐educational blended (group and online) intervention HypoAware compared with usual care for people with Type 1 and insulin‐treated Type 2 diabetes with problematic hypoglycaemia: analyses of a cluster‐randomized controlled
M. de Wit, S. M. P. A. Rondags, M. W. van Tulder, F. J. Snoek, J. E. Bosmans
Diabetic Medicine.2018; 35(2): 214. CrossRef
Dynamin-related protein 1 mediates low glucose-induced endothelial dysfunction in human arterioles
Michael J. Tanner, Jingli Wang, Rong Ying, Tisha B. Suboc, Mobin Malik, Allison Couillard, Amberly Branum, Venkata Puppala, Michael E. Widlansky
American Journal of Physiology-Heart and Circulatory Physiology.2017; 312(3): H515. CrossRef
Hazardous factors besides infection in hypoglycemia
Yu-Jang Su, Yen-Chun Lai, Chia-Jung Liao
Biomedical Reports.2017; 6(4): 480. CrossRef
Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus from Korea
Gyuri Kim, Yong-ho Lee, Mi Hye Han, Eui-Kyung Lee, Chong Hwa Kim, Hyuk Sang Kwon, In Kyung Jeong, Eun Seok Kang, Dae Jung Kim, Massimo Pietropaolo
PLOS ONE.2016; 11(3): e0151282. CrossRef
Costs associated with emergency care and hospitalization for severe hypoglycemia
G. Veronese, G. Marchesini, G. Forlani, S. Saragoni, L. Degli Esposti, E. Centis, A. Fabbri
Nutrition, Metabolism and Cardiovascular Diseases.2016; 26(4): 345. CrossRef
Risk of hospitalization for hypoglycemia among older Korean people with diabetes mellitus
Hyun Min Kim, Jong-Mi Seong, Jaetaek Kim
Medicine.2016; 95(42): e5016. CrossRef
Risk factors of severe hypoglycemia requiring medical assistance and neurological sequelae in patients with diabetes
Ja Young Jeon, Se Ran Kim, Hae Jin Kim, Dae Jung Kim, Kwan-Woo Lee, Jung-Dong Lee, Seung Jin Han
Medicine.2016; 95(47): e5365. CrossRef
Effectiveness of HypoAware, a Brief Partly Web-Based Psychoeducational Intervention for Adults With Type 1 and Insulin-Treated Type 2 Diabetes and Problematic Hypoglycemia: A Cluster Randomized Controlled Trial
Stefanie M.P.A. Rondags, Maartje de Wit, Jos W. Twisk, Frank J. Snoek
Diabetes Care.2016; 39(12): 2190. CrossRef
The cost of managing severe hypoglycemic episodes in Type 2 diabetic patients
Pedro Almeida Laires, João Conceição, Francisco Araújo, Jorge Dores, Catarina Silva, Larry Radican, Ana Nogueira
Expert Review of Pharmacoeconomics & Outcomes Research.2016; 16(2): 315. CrossRef
HypoAware: development and pilot study of a brief and partly web‐based psychoeducational group intervention for adults with Type 1 and insulin‐treated Type 2 diabetes and problematic hypoglycaemia
S. M. P. A. Rondags, M. de Wit, F. J. Snoek
Diabetic Medicine.2016; 33(2): 184. CrossRef
Hypoglycemia and Health Costs
Yong-ho Lee, Gyuri Kim, Eun Seok Kang
The Journal of Korean Diabetes.2016; 17(1): 11. CrossRef
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
Jae-Seung Yun, Seung-Hyun Ko
The Korean Journal of Internal Medicine.2015; 30(1): 6. CrossRef
1,5-Anhydroglucitol as a Useful Marker for Assessing Short-Term Glycemic Excursions in Type 1 Diabetes
Hannah Seok, Ji Hye Huh, Hyun Min Kim, Byung-Wan Lee, Eun Seok Kang, Hyun Chul Lee, Bong Soo Cha
Diabetes & Metabolism Journal.2015; 39(2): 164. CrossRef
Intensive Individualized Reinforcement Education Is Important for the Prevention of Hypoglycemia in Patients with Type 2 Diabetes
Yun-Mi Yong, Kyung-Mi Shin, Kang-Min Lee, Jae-Young Cho, Sun-Hye Ko, Min-Hyang Yoon, Tae-Won Kim, Jong-Hyun Jeong, Yong-Moon Park, Seung-Hyun Ko, Yu-Bae Ahn
Diabetes & Metabolism Journal.2015; 39(2): 154. CrossRef
Hypoglycaemia in elderly patients with type 2 diabetes mellitus: a review of risk factors, consequences and prevention
Badieh Jafari, Mary E. Britton
Journal of Pharmacy Practice and Research.2015; 45(4): 459. CrossRef
HypoAware-a brief and partly web-based psycho-educational group intervention for adults with type 1 and insulin-treated type 2 diabetes and problematic hypoglycaemia: design of a cost-effectiveness randomised controlled trial
Stefanie MPA Rondags, Maartje de Wit, Maurits W van Tulder, Michaela Diamant, Frank J. Snoek
BMC Endocrine Disorders.2015;[Epub] CrossRef
Hypoglycemia in Emergency Department
Yu-Jang Su, Chia-Jung Liao
Journal of Acute Disease.2015; 4(1): 59. CrossRef
Should Sulfonylureas Remain an Acceptable First-Line Add-on to Metformin Therapy in Patients With Type 2 Diabetes? Yes, They Continue to Serve Us Well!
Martin J. Abrahamson
Diabetes Care.2015; 38(1): 166. CrossRef
Association Between Hypoglycemia and Fall-Related Events in Type 2 Diabetes Mellitus: Analysis of a U.S. Commercial Database
Sumesh Kachroo, Hugh Kawabata, Susan Colilla, Lizheng Shi, Yingnan Zhao, Jayanti Mukherjee, Uchenna Iloeje, Vivian Fonseca
Journal of Managed Care & Specialty Pharmacy.2015; 21(3): 243. CrossRef
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes
Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey, Michelle A. Baron
Journal of Diabetes and its Complications.2014; 28(3): 393. CrossRef
Management of Diabetes Medications for Patients Undergoing Ambulatory Surgery
Mary Ann Vann
Anesthesiology Clinics.2014; 32(2): 329. CrossRef
Principales factores asociados al coste de la diabetes mellitus tipo 2: revisión de la literatura
Silvia Paz, Diego González Segura, Anna Raya Torres, Luis Lizan
Avances en Diabetología.2014; 30(2): 34. CrossRef
Incidence of hypoglycaemia associated with transient loss of consciousness. A retrospective cohort study
A. Lagi, S. Cencetti, F. Lagi
International Journal of Clinical Practice.2014; 68(8): 1029. CrossRef
Hypoglycemia in Patients with Type 1 Diabetes: Epidemiology, Pathogenesis, and Prevention
Omodele Awoniyi, Rabia Rehman, Samuel Dagogo-Jack
Current Diabetes Reports.2013; 13(5): 669. CrossRef
Diabetes: support for those at risk of malnutrition in the community
Siobhan Hughes
British Journal of Community Nursing.2012; 17(11): 529. CrossRef
Diabetes patients at risk of malnutrition
Siobhan Hughes
Independent Nurse.2012;[Epub] CrossRef
Type 2 diabetes: the evolution of a disease
Harold E Lebovitz
The British Journal of Diabetes & Vascular Disease.2012; 12(6): 290. CrossRef
Severe Hypoglycemia in Patients with Diabetes
Jae Seung Yun, Seung-Hyun Ko
Diabetes & Metabolism Journal.2012; 36(4): 273. CrossRef

Author index